JAMA+ AI Weekly Update: August 9, 2025

In a new episode of JAMA+ AI Conversations, JAMA+ AI Editor-in-Chief Roy Perlis, MD, talks with David Rhew, MD, Microsoft’s Chief Medical Officer, about his path from clinical practice to technology leadership, the rapid evolution of AI, and its implications for health.

Learn more and listen to the podcast.

Editor’s Picks in this week’s JAMA+ AI:

• The FDA's draft guidance on AI in drug development provides a framework for AI model credibility. The use of pediatric digital twins (virtual models of systems) illustrates the need for more specific ethical regulations related to pediatric drug and device discovery. Read this Viewpoint in JAMA Pediatrics.
• Machine learning models trained on patient-reported data may help predict future flares and disease severity in atopic dermatitis. A recent Original Investigation in JAMA Dermatology highlights how flare frequency, duration, and severity could inform treatment decisions and improve quality of life.
• As AI tools become more embedded in clinical care, what should patients be told? Clinicians need a practical framework for when to notify or seek consent from patients about AI use, balancing ethical obligations, legal standards, and risk of harm. This JAMA Perspective provides suggested language.